Mackenzie Financial’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $465M | Buy |
506,081
+14,768
| +3% | +$15M | 0.56% | 38 |
|
|
2025
Q4 | $529M | Buy |
491,313
+230,015
| +88% | +$220M | 0.63% | 30 |
|
|
2025
Q3 | $199M | Buy |
261,298
+37,425
| +17% | +$27.9M | 0.24% | 90 |
|
|
2025
Q2 | $175M | Sell |
223,873
-28,561
| -11% | -$22.2M | 0.23% | 102 |
|
|
2025
Q1 | $208M | Sell |
252,434
-22,047
| -8% | -$18.3M | 0.3% | 87 |
|
|
2024
Q4 | $212M | Buy |
274,481
+5,577
| +2% | +$4.62M | 0.29% | 85 |
|
|
2024
Q3 | $238M | Sell |
268,904
-10,247
| -4% | -$9.21M | 0.33% | 81 |
|
|
2024
Q2 | $253M | Sell |
279,151
-2,598
| -0.9% | -$2.08M | 0.38% | 67 |
|
|
2024
Q1 | $219M | Sell |
281,749
-13,257
| -4% | -$9.43M | 0.32% | 87 |
|
|
2023
Q4 | $172M | Sell |
295,006
-44,713
| -13% | -$26.1M | 0.26% | 97 |
|
|
2023
Q3 | $178M | Buy |
339,719
+16,045
| +5% | +$8.27M | 0.3% | 86 |
|
|
2023
Q2 | $149M | Buy |
323,674
+53,501
| +20% | +$22.4M | 0.23% | 106 |
|
|
2023
Q1 | $92.8M | Buy |
270,173
+2,899
| +1% | +$978K | 0.14% | 152 |
|
|
2022
Q4 | $97.8M | Buy |
267,274
+8,366
| +3% | +$2.97M | 0.16% | 143 |
|
|
2022
Q3 | $83.7M | Buy |
258,908
+14,878
| +6% | +$4.71M | 0.14% | 157 |
|
|
2022
Q2 | $79.1M | Buy |
244,030
+67,952
| +39% | +$20.4M | 0.13% | 167 |
|
|
2022
Q1 | $50.4M | Sell |
176,078
-28,077
| -14% | -$7.23M | 0.07% | 229 |
|
|
2021
Q4 | $56.4M | Sell |
204,155
-37,349
| -15% | -$9.47M | 0.08% | 226 |
|
|
2021
Q3 | $55.8M | Sell |
241,504
-23,523
| -9% | -$5.81M | 0.08% | 220 |
|
|
2021
Q2 | $60.8M | Sell |
265,027
-25,087
| -9% | -$5.04M | 0.08% | 211 |
|
|
2021
Q1 | $54.2M | Buy |
290,114
+8,627
| +3% | +$1.69M | 0.08% | 198 |
|
|
2020
Q4 | $47.5M | Buy |
281,487
+11,988
| +4% | +$1.79M | 0.1% | 185 |
|
|
2020
Q3 | $39.9M | Buy |
269,499
+27,465
| +11% | +$4.25M | 0.1% | 191 |
|
|
2020
Q2 | $39.7M | Buy |
242,034
+99,285
| +70% | +$15.2M | 0.11% | 188 |
|
|
2020
Q1 | $19.8M | Sell |
142,749
-5,434
| -4% | -$747K | 0.06% | 217 |
|
|
2019
Q4 | $19.5M | Buy |
148,183
+58,544
| +65% | +$6.79M | 0.05% | 249 |
|
|
2019
Q3 | $10M | Buy |
89,639
+5,077
| +6% | +$565K | 0.03% | 333 |
|
|
2019
Q2 | $9.37M | Sell |
84,562
-29,498
| -26% | -$3.47M | 0.02% | 325 |
|
|
2019
Q1 | $14.8M | Sell |
114,060
-18,264
| -14% | -$2.22M | 0.04% | 315 |
|
|
2018
Q4 | $15.3M | Buy |
132,324
+78,474
| +146% | +$8.77M | 0.04% | 299 |
|
|
2018
Q3 | $5.78M | Buy |
53,850
+10,109
| +23% | +$1.01M | 0.01% | 464 |
|
|
2018
Q2 | $3.73M | Buy |
43,741
+13,486
| +45% | +$1.11M | 0.01% | 504 |
|
|
2018
Q1 | $2.34M | Buy |
30,255
+17,644
| +140% | +$1.42M | 0.01% | 541 |
|
|
2017
Q4 | $1.06M | Buy |
+12,611
| New | +$1.07M | ﹤0.01% | 598 |
|
|
2016
Q3 | – | Sell |
-63,769
| Closed | -$5.02M | – | 780 |
|
|
2016
Q2 | $5.02M | Buy |
63,769
+5,695
| +10% | +$429K | 0.03% | 320 |
|
|
2016
Q1 | $4.18M | Sell |
58,074
-18,959
| -25% | -$1.43M | 0.04% | 274 |
|
|
2015
Q4 | $6.49M | Buy |
77,033
+6,450
| +9% | +$535K | 0.04% | 290 |
|
|
2015
Q3 | $5.91M | Buy |
70,583
+28,255
| +67% | +$2.39M | 0.04% | 282 |
|
|
2015
Q2 | $3.53M | Buy |
42,328
+2,808
| +7% | +$214K | 0.02% | 349 |
|
|
2015
Q1 | $2.87M | Buy |
39,520
+4,049
| +11% | +$288K | 0.02% | 376 |
|
|
2014
Q4 | $2.45M | Sell |
35,471
-11,572
| -25% | -$781K | 0.01% | 397 |
|
|
2014
Q3 | $3.05M | Buy |
47,043
+30,848
| +190% | +$1.95M | 0.02% | 349 |
|
|
2014
Q2 | $1.01M | Buy |
16,195
+2,771
| +21% | +$165K | ﹤0.01% | 511 |
|
|
2014
Q1 | $790K | Sell |
13,424
-879
| -6% | -$49.1K | ﹤0.01% | 542 |
|
|
2013
Q4 | $729K | Buy |
14,303
+3,682
| +35% | +$184K | ﹤0.01% | 550 |
|
|
2013
Q3 | $535K | Buy |
10,621
+611
| +6% | +$32K | ﹤0.01% | 567 |
|
|
2013
Q2 | $492K | Buy |
+10,010
| New | +$545K | ﹤0.01% | 585 |
|
Other funds holding LLY
VCM
VPM
Mackenzie Financial's LLY Position: Q1 2026 in Review
Mackenzie Financial increased its Eli Lilly (LLY) stake by 3% in Q1 2026, buying an estimated $15M and bringing the position to 506,081 shares worth $465M. The position accounts for 0.56% of the portfolio, ranked #38.
Mackenzie Financial first reported a position in LLY in Q2 2013 and has held it in 47 quarters since. The position peaked at $529M in Q4 2025. 4,353 funds tracked by Wall St. Rank hold LLY as of Q1 2026.
- Mackenzie Financial held 506,081 shares of Eli Lilly worth $465M as of Q1 2026.
- Mackenzie Financial bought 14,768 Eli Lilly shares in Q1 2026, an estimated $15M.
- Eli Lilly made up 0.56% of Mackenzie Financial's portfolio in Q1 2026, its #38 holding.
- Mackenzie Financial first reported a position in Eli Lilly in Q2 2013 and has held it in 47 quarters since.
- Mackenzie Financial's Eli Lilly position peaked at $529M in Q4 2025.
- 4,353 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.
Based on Mackenzie Financial's 13F filing for Q1 2026, filed 13 May 2026.